Transplantation of neural stem cells improved neurologic and motor function for adults with chronic ischemic stroke at 12 ...

In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE.

Outside of stroke, tDCS has had major setbacks in recent years. The DepressionDC study found it to be no better than sham as ...

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

Remedy Pharmaceuticals, a leader in stroke drug development today announced efficacy data from the Phase 2 GAMES-RP and Phase 3 CHARM studies of CIRARA (intravenous glyburide) for the treatment of ...

Three trials showed no improvement in functional outcomes, and the potential for harm, versus medical therapy alone.

Background: We investigate whether the NIHSS at 24 hours could serve as an alternative primary outcome measure in acute ischemic stroke trials, and whether combining 90-day modified Rankin Score (mRS) ...

Figure 1. Study flowchart. TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; LKWA, last-known-well-to-arrival time; mRS, modified Rankin Scale. Table 1. Baseline ...

The primary outcome measure was a favorable modified Rankin Scale (mRS = 0-2) at day 90. Secondary parameters included the NIHSS, the Montreal Cognitive Assessment (MoCA), the rate of hemorrhagic ...

1 Factors such as age, National Institutes of Health Stroke Scale (NIHSS) score at baseline ... for the subgroup with excellent reperfusion (eTICI ≥2C) and (2) using a modified NIHSS score at 24–48 ...

The primary outcome was favorable functional outcome (modified Rankin Scale score 0–3 ... as an mRS of 0–2); the proportion of patients with an mRS score of 0–4; NIHSS score at discharge; and ...